🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Could incretin-based therapies be the future of neurodegenerative disease treatment? Originally for diabetes & obesity, GLP-1R agonists show promise in reducing neuroinflammation & enhancing brain health. A potential game-changer in #NDD management. nature.com/articles/s4225…

Neurodegenerative diseases share common hallmarks, such as protein aggregation, offering therapeutic opportunities. Targeting multiple shared mechanisms including GLP receptors could yield additive clinical benefits. Differences in affected brain regions drive distinct symptoms.

Honored to be an author-alongside so many prestigious coauthors-on this important work tackling obesity in primary care. sciencedirect.com/science/articl…

GLP-1 receptor agonists: more than glycemic control and weight loss. They reduce inflammation, improve cardiovascular & kidney health, and may benefit neurodegenerative & psychiatric conditions. Clinical trials are unlocking their full potential. #GLP1 nature.com/articles/s4225…

Diagnosis tools for MASLD in the management of obesity. sciencedirect.com/science/articl…

GLP-1 receptors are found in key brain regions tied to neurodegenerative diseases—hippocampus, brainstem (locus coeruleus), thalamus, amygdala, and cingulate cortex. Their widespread presence suggests therapeutic potential for Alzheimer’s, Parkinson’s, and progressive

MASLD pathway for PCPs. sciencedirect.com/science/articl…

Tirzepatide was superior to semaglutide with respect to weight loss and waist circumference at week 72. nejm.org/doi/full/10.10…

Mean percent weight loss change was 21.6% with #tirzepatide vs. 15.4% with #semaglutide in SURMOUNT-5. nejm.org/doi/full/10.10…

Tirzepatide leads to greater weight loss and waist reduction than semaglutide at max doses. In a 72-week study, tirzepatide users lost up to 21% of body weight vs ~10% with semaglutide. More tirzepatide users hit ≥10%, 15%, 20%, and 25% weight loss targets. Waist circumference

Treatment options for MASLD. sciencedirect.com/science/articl…

Looking forward to #AACE2025

Great to see AACE Past Presidents at #AACE2025

Ribbon cutting ceremony to open the Learning Zone at #AACE2025

AACE past presidents’ dinner. #AACE2025

Congratulations to this year’s Annual Meeting Chair, Dr. Cecilia Low Wang! 🎉 Your leadership and dedication made our meeting a huge success. Thank you for bringing everyone together and inspiring us all!

Come learn about MASLD tomorrow at #AACE2025. Jeffrey V. Lazarus

Thrilled to have my father join me at #AACE2025.

Below age 35 and above 65 FIB 4 may not work ..Scott Isaacs AACE ..fibroscan or els...#AACE2025...

It was an incredible honor to meet Daniel J Drucker before his keynote address at #AACE2025.